The modified WHO analgesic ladder: is it appropriate for chronic non-cancer pain?

J Yang, BA Bauer, DL Wahner-Roedler… - Journal of pain …, 2020 - Taylor & Francis
Introduction From 1986, the World Health Organization (WHO) analgesic ladder has been
used as the simple and valuable pain-relieving guidance in the pharmaceutical pain …

[HTML][HTML] Drivers of the opioid crisis: an appraisal of financial conflicts of interest in clinical practice guideline panels at the peak of opioid prescribing

S Spithoff, P Leece, F Sullivan, N Persaud, P Belesiotis… - PloS one, 2020 - journals.plos.org
Background Starting in the late 1990s, the pharmaceutical industry sought to increase
prescribing of opioids for chronic non-cancer pain. Influencing the content of clinical practice …

Replacement of current opioid drugs focusing on MOR-related strategies

J Busserolles, S Lolignier, N Kerckhove, C Bertin… - Pharmacology & …, 2020 - Elsevier
The scarcity and limited risk/benefit ratio of painkillers available on the market, in addition to
the opioid crisis, warrant reflection on new innovation strategies. The pharmacopoeia of …

Management of opioid use disorder in the emergency department: a white paper prepared for the American Academy of Emergency Medicine

RJ Strayer, K Hawk, BD Hayes, AA Herring… - The Journal of …, 2020 - Elsevier
Over 2 million Americans misuse prescription or illicitly obtained opioids, and opioid
overdose deaths rose to a record 47,600 in 2017, representing a nearly 600% increase in …

[HTML][HTML] “My life is under control with these medications”: an interpretative phenomenological analysis of managing chronic pain with opioids

H Ljungvall, A Rhodin, S Wagner, H Zetterberg… - BMC musculoskeletal …, 2020 - Springer
Background The use of opioids to relieve chronic pain has increased during the last
decades, but experiences of chronic opioid therapy (COT)(> 90 days) point at risks and loss …

Corydaline and l-tetrahydropalmatine attenuate morphine-induced conditioned place preference and the changes in dopamine D2 and GluA1 AMPA receptor …

WN Jiang, X Jing, M Li, H Deng, T Jiang… - European Journal of …, 2020 - Elsevier
Corydalis is a Chinese herb that has been used in China for hundreds of years for analgesic
and other purposes. Corydaline and l-tetrahydropalmatine (l-THP) are the main active …

Efficacy of a psychosocial pain management intervention for men and women with substance use disorders and chronic pain: A randomized clinical trial

MA Ilgen, LN Coughlin, ASB Bohnert… - JAMA …, 2020 - jamanetwork.com
Importance Chronic pain is common in those with substance use disorders (SUDs) and
predicts poorer addiction treatment outcomes. A critical challenge for addiction treatment is …

[HTML][HTML] Increased risk of adverse events in non-cancer patients with chronic and high-dose opioid use—A health insurance claims analysis

JM Burgstaller, U Held, A Signorell, E Blozik… - PLoS …, 2020 - journals.plos.org
Background Chronic and high dose opioid use may result in adverse events. We analyzed
the risk associated with chronic and high dose opioid prescription in a Swiss population …

[HTML][HTML] Increasing system-wide implementation of opioid prescribing guidelines in primary care: findings from a non-randomized stepped-wedge quality improvement …

AE Zgierska, JM Robinson, RP Lennon, PD Smith… - BMC Family …, 2020 - Springer
Background Clinician utilization of practice guidelines can reduce inappropriate opioid
prescribing and harm in chronic non-cancer pain; yet, implementation of “opioid guidelines” …

[HTML][HTML] Chronic non-malignant pain in patients with cancer seen at a timely outpatient palliative care clinic

D Hui, E Abdelghani, J Chen, S Dibaj, D Zhukovsky… - Cancers, 2020 - mdpi.com
Palliative care is seeing cancer patients earlier in the disease trajectory with a multitude of
chronic issues. Chronic non-malignant pain (CNMP) in cancer patients is under-studied. In …